AccueilSAVA • NASDAQ
add
Cassava Sciences Inc
Dernière clôture
2,83 $
Variation sur la journée
2,76 $ - 2,91 $
Plage sur l'année
2,23 $ - 42,20 $
Capitalisation boursière
135,53 M USD
Volume moyen
9,63 M
Ratio cours/bénéfices
-
Rendement (dividendes)
-
Place boursière principale
NASDAQ
Données financières
Compte de résultat
Chiffre d'affaires
Résultat net
| (USD) | sept. 2024info | Variation Y/Y |
|---|---|---|
Chiffre d'affaires | — | — |
Charges d'exploitation | 14,05 M | 228,51 % |
Résultat net | -27,94 M | -8,94 % |
Marge bénéficiaire nette | — | — |
Bénéfice par action | -0,58 | 4,92 % |
EBITDA | -31,46 M | -14,47 % |
Taux d'imposition effectif | — | — |
Bilan
Total des actifs
Total du passif
| (USD) | sept. 2024info | Variation Y/Y |
|---|---|---|
Trésorerie/Invest. court terme | 148,98 M | 4,66 % |
Total des actifs | 223,75 M | 29,69 % |
Total du passif | 57,11 M | 227,98 % |
Total des capitaux propres | 166,64 M | — |
Actions en circulation | 48,11 M | — |
Ratio cours/valeur comptable | 0,81 | — |
Rentabilité des actifs | -33,94 % | — |
Retour sur capitaux | -44,60 % | — |
Flux de trésorerie
Variation nette en trésorerie
| (USD) | sept. 2024info | Variation Y/Y |
|---|---|---|
Résultat net | -27,94 M | -8,94 % |
Trésorerie (opérations) | -18,30 M | 31,04 % |
Trésorerie (invest.) | -17,00 k | 22,73 % |
Trésorerie (financement) | 0,00 | -100,00 % |
Variation nette en trésorerie | -18,31 M | 29,80 % |
Flux de trésorerie dispo. | -50,28 M | -174,35 % |
À propos
Cassava Sciences is an American pharmaceutical company based in Austin, Texas. The company was developing simufilam, an oral-tablet drug candidate for the treatment of Alzheimer's disease. Development of simufilam was discontinued in November 2024 after it failed to show clinical benefit in phase III clinical trials.
In June 2024, the United States Department of Justice charged an advisor to Cassava Sciences, Hoau-Yan Wang, with fraud over research results related to the experimental drug. Less than a month later, the president, chief executive officer and chairman of the board, Remi Barbier, resigned along with Lindsay Burns, his wife, who was a Cassava senior vice president and Wang's co-author. The U.S. Securities and Exchange Commission filed fraud charges in September 2024 against Cassava, Barbier, Burns and Wang. The parties did not admit wrongdoing, but a settlement of the SEC charges, pending court approval, would fine Cassava $US40 million, Barbier $175 thousand, Burns $85 thousand and Wang $50 thousand.
Cassava was founded in 1998 by Remi Barbier as Pain Therapeutics, Inc., changing its name in 2019. Wikipedia
Date de fondation
1998
Siège social
Site Web
Employés
29
